The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study

Mario E. Beiner, Amy Finch, Barry Rosen, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry T. Lynch, Eitan Friedman, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Objective: To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes. Patients and methods: Women known to carry a BRCA1 or BRCA2 mutation, aged 45 to 70, were identified from an international registry and were followed prospectively. A total of 857 women completed a baseline questionnaire and one or more follow-up questionnaires. Study subjects were followed until diagnosis of endometrial cancer, ovarian cancer, death or the date of completion of the last questionnaire. The expected number of endometrial cancers was calculated using age and country-specific incidence rates. Results: After an average follow-up period of 3.3 years, six women were diagnosed with endometrial cancer, compared to 1.13 cancers expected (SIR = 5.3, p = 0.0011). Four of these six patients used tamoxifen in the past. The risk among women who were never exposed to tamoxifen treatment was not significantly elevated (SIR = 2.7, p = 0.17), but among the 226 participants who had used tamoxifen (220 as treatment and six for the primary prevention of breast cancer) the relative risk for endometrial cancer was 11.6 (p = 0.0004). Conclusion: The main contributor to the increased risk of endometrial cancer among BRCA carriers is tamoxifen treatment for a previous breast cancer. The risk and benefits of prophylactic hysterectomy should be discussed with women with a BRCA mutation considering tamoxifen therapy.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalGynecologic Oncology
Volume104
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Endometrial Neoplasms
Tamoxifen
Prospective Studies
Mutation
BRCA2 Gene
Breast Neoplasms
BRCA1 Gene
Primary Prevention
Therapeutics
Hysterectomy
Ovarian Neoplasms
Registries
Incidence
Surveys and Questionnaires
Neoplasms

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Cite this

Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P., ... Narod, S. A. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 104(1), 7-10. https://doi.org/10.1016/j.ygyno.2006.08.004

The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. / Beiner, Mario E.; Finch, Amy; Rosen, Barry; Lubinski, Jan; Moller, Pal; Ghadirian, Parviz; Lynch, Henry T.; Friedman, Eitan; Sun, Ping; Narod, Steven A.

In: Gynecologic Oncology, Vol. 104, No. 1, 01.2007, p. 7-10.

Research output: Contribution to journalArticle

Beiner, ME, Finch, A, Rosen, B, Lubinski, J, Moller, P, Ghadirian, P, Lynch, HT, Friedman, E, Sun, P & Narod, SA 2007, 'The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study', Gynecologic Oncology, vol. 104, no. 1, pp. 7-10. https://doi.org/10.1016/j.ygyno.2006.08.004
Beiner, Mario E. ; Finch, Amy ; Rosen, Barry ; Lubinski, Jan ; Moller, Pal ; Ghadirian, Parviz ; Lynch, Henry T. ; Friedman, Eitan ; Sun, Ping ; Narod, Steven A. / The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. In: Gynecologic Oncology. 2007 ; Vol. 104, No. 1. pp. 7-10.
@article{0d581dbe72224d95ad445cb94891df72,
title = "The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study",
abstract = "Objective: To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes. Patients and methods: Women known to carry a BRCA1 or BRCA2 mutation, aged 45 to 70, were identified from an international registry and were followed prospectively. A total of 857 women completed a baseline questionnaire and one or more follow-up questionnaires. Study subjects were followed until diagnosis of endometrial cancer, ovarian cancer, death or the date of completion of the last questionnaire. The expected number of endometrial cancers was calculated using age and country-specific incidence rates. Results: After an average follow-up period of 3.3 years, six women were diagnosed with endometrial cancer, compared to 1.13 cancers expected (SIR = 5.3, p = 0.0011). Four of these six patients used tamoxifen in the past. The risk among women who were never exposed to tamoxifen treatment was not significantly elevated (SIR = 2.7, p = 0.17), but among the 226 participants who had used tamoxifen (220 as treatment and six for the primary prevention of breast cancer) the relative risk for endometrial cancer was 11.6 (p = 0.0004). Conclusion: The main contributor to the increased risk of endometrial cancer among BRCA carriers is tamoxifen treatment for a previous breast cancer. The risk and benefits of prophylactic hysterectomy should be discussed with women with a BRCA mutation considering tamoxifen therapy.",
author = "Beiner, {Mario E.} and Amy Finch and Barry Rosen and Jan Lubinski and Pal Moller and Parviz Ghadirian and Lynch, {Henry T.} and Eitan Friedman and Ping Sun and Narod, {Steven A.}",
year = "2007",
month = "1",
doi = "10.1016/j.ygyno.2006.08.004",
language = "English",
volume = "104",
pages = "7--10",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study

AU - Beiner, Mario E.

AU - Finch, Amy

AU - Rosen, Barry

AU - Lubinski, Jan

AU - Moller, Pal

AU - Ghadirian, Parviz

AU - Lynch, Henry T.

AU - Friedman, Eitan

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2007/1

Y1 - 2007/1

N2 - Objective: To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes. Patients and methods: Women known to carry a BRCA1 or BRCA2 mutation, aged 45 to 70, were identified from an international registry and were followed prospectively. A total of 857 women completed a baseline questionnaire and one or more follow-up questionnaires. Study subjects were followed until diagnosis of endometrial cancer, ovarian cancer, death or the date of completion of the last questionnaire. The expected number of endometrial cancers was calculated using age and country-specific incidence rates. Results: After an average follow-up period of 3.3 years, six women were diagnosed with endometrial cancer, compared to 1.13 cancers expected (SIR = 5.3, p = 0.0011). Four of these six patients used tamoxifen in the past. The risk among women who were never exposed to tamoxifen treatment was not significantly elevated (SIR = 2.7, p = 0.17), but among the 226 participants who had used tamoxifen (220 as treatment and six for the primary prevention of breast cancer) the relative risk for endometrial cancer was 11.6 (p = 0.0004). Conclusion: The main contributor to the increased risk of endometrial cancer among BRCA carriers is tamoxifen treatment for a previous breast cancer. The risk and benefits of prophylactic hysterectomy should be discussed with women with a BRCA mutation considering tamoxifen therapy.

AB - Objective: To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes. Patients and methods: Women known to carry a BRCA1 or BRCA2 mutation, aged 45 to 70, were identified from an international registry and were followed prospectively. A total of 857 women completed a baseline questionnaire and one or more follow-up questionnaires. Study subjects were followed until diagnosis of endometrial cancer, ovarian cancer, death or the date of completion of the last questionnaire. The expected number of endometrial cancers was calculated using age and country-specific incidence rates. Results: After an average follow-up period of 3.3 years, six women were diagnosed with endometrial cancer, compared to 1.13 cancers expected (SIR = 5.3, p = 0.0011). Four of these six patients used tamoxifen in the past. The risk among women who were never exposed to tamoxifen treatment was not significantly elevated (SIR = 2.7, p = 0.17), but among the 226 participants who had used tamoxifen (220 as treatment and six for the primary prevention of breast cancer) the relative risk for endometrial cancer was 11.6 (p = 0.0004). Conclusion: The main contributor to the increased risk of endometrial cancer among BRCA carriers is tamoxifen treatment for a previous breast cancer. The risk and benefits of prophylactic hysterectomy should be discussed with women with a BRCA mutation considering tamoxifen therapy.

UR - http://www.scopus.com/inward/record.url?scp=33845968075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845968075&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.08.004

DO - 10.1016/j.ygyno.2006.08.004

M3 - Article

VL - 104

SP - 7

EP - 10

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -